Update on antiobesity medications in adults PART ONE

Complement inhibition PART TWO

In this two-part podcast featuring the Cleveland Clinic Journal of Medicine article, “Complement inhibition: A whole new world,” lead author Dr. Nicholas Salupo, and senior author, Dr. Ali Mehdi, Cleveland Clinic, join moderator Dr. Narbeh Melikian, Cleveland Clinic London. The trio discusses the complement system, a central component of the innate immune system, and bridge to the adaptive immune system.

Complement inhibition PART ONE

In this two-part podcast featuring the Cleveland Clinic Journal of Medicine article, “Complement inhibition: A whole new world,” lead author Dr. Nicholas Salupo, and senior author, Dr. Ali Mehdi, Cleveland Clinic, join moderator Dr. Narbeh Melikian, Cleveland Clinic London. The trio discusses the complement system, a central component of the innate immune system, and bridge to the adaptive immune system.

Update on antiobesity medications in adults PART TWO

In this two-part podcast featuring the Cleveland Clinic Journal of Medicine article, “Update on antiobesity pharmacotherapy in adults: Current and emerging options,” Dr. Farah Ziyadeh, and Dr. Yael Mauer, Cleveland Clinic, join moderator Dr. Craig Nielsen, Cleveland Clinic. The trio discusses available antiobesity medications, including the incretin mimetics, and emerging antiobesity medications currently under investigation.

Update on antiobesity medications in adults PART ONE

In this two-part podcast featuring the Cleveland Clinic Journal of Medicine article, “Update on antiobesity pharmacotherapy in adults: Current and emerging options,” Dr. Farah Ziyadeh, and Dr. Yael Mauer, Cleveland Clinic, join moderator Dr. Craig Nielsen, Cleveland Clinic. The trio discusses available antiobesity medications, including the incretin mimetics, and emerging antiobesity medications currently under investigation.

Lipoprotein(a) in clinical practice

Listen as Dr. Astefanos Al-Dalakta and Dr. Ashish Sarraju, Cleveland Clinic, join moderator Dr. George Thomas, Cleveland Clinic, to discuss what clinicians need to know about lipoprotein(a) in clinical practice. Topics discussed include summarizes evidence on risk, screening strategies, and evolving therapies for elevated lipoprotein(a).